GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

glutazumab   Click here for help

GtoPdb Ligand ID: 14316

Synonyms: GMA-102
Compound class: Antibody
Comment: Glutazumab (GMA102, Gmax Biopharm) is a monoclonal antibody fusion protein that behaves as a long-acting agonist at the glucagon like-peptide-1 (GLP-1) receptor [1]. It combines a humanized IgG2 monoclonal antibody against the GLP-1 receptor and a proteolysis-resistant derivative of human GLP-1 (7-35). Both the antibody component and GLP-1 ligand moiety of glutazumab are reported to contribute to the binding and activation of the receptor.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Glutazumab (GMA102) was progressed to clinical evaluations as a novel therapeutic for type 2 diabetes mellitus. Phase 2 trial ACTRN12617000811303 was conducted in Australia/New Zealand during 2017-2020, and phase 3 is being conducted in China.